Introduction
============

Abnormal angiogenesis in malignant tumors usually results in structurally and functionally deficient new blood vessels [@B1]. These vessels are disorganized, tortuous, and rather leaky, leading to heterogeneous blood flow, hypoxia, acidosis, and elevated interstitial fluid pressure (IFP) [@B2]. The highly abnormal blood vessels in tumors lead to enhanced permeability and retention (EPR) [@B3], which is a well-established phenomenon in solid tumors and has been exploited to facilitate delivery of high-molecular-weight drugs or nano-formulations to the site of diseases [@B4]. Moreover, angiogenesis and vasculature vary in different tumor types and even in different stages of tumor development [@B5]. Therefore, the ability to evaluate vascular permeability would be of great value in predicting drug delivery efficiency, monitoring tumor vascular alteration early during antiangiogenic therapy, and shedding light on the initiation and progression of solid tumors [@B6].

In preclinical studies, the gold standard to evaluate vascular permeability is colorimetric spectrophotometry after intravenous injection and extraction of Evans Blue (EB), an azo dye that binds quantitatively with serum proteins, mainly albumin [@B7]-[@B10]. Following increased vascular permeability to large biomolecules, EB extravasates to the interstitial space along with albumin [@B11]. Organs with enhanced permeability show significantly increased blue coloration over organs with intact endothelium. The other techniques include cannulation of a single microvessel with a micropipette [@B12] or using multiphoton fluorescence intravital microscopy [@B13]. However, all these methods are either invasive or technically demanding and are subjected to sampling errors, and thus do not have much clinical significance.

Within the last decade, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with two-compartment kinetic modeling has shown potential in quantitatively assessing certain properties of tumor tissue, particularly vascular permeability and blood flow [@B14]-[@B17]. Consequently, DCE-MRI is currently in wide use as a means of assessing early response to antiangiogenic therapy in clinical trials [@B18]. However, the degree of signal enhancement with DCE-MRI depends on several physiological and physical characteristics, including contrast concentration, tissue perfusion, permeability, and volume of extracellular extravascular space. Therefore, there is controversy over the physiological meaning of parameters derived from DCE-MRI, as well as concerns over the reproducibility of such measurements [@B19]. Besides, implementation of DCE-MRI into clinical imaging protocols suffers from several challenges including the complexity in image acquisition and pharmacokinetic model post-processing, and the lack of widely available and easy-to-use post-processing software [@B20]. Moreover, DCE-MRI may not be feasible for some patient groups, especially individuals with renal failure due to the potential toxicity of the gadolinium-based contrast agents and those with implanted metallic devices.

Among all the imaging modalities used clinically, positron emission tomography (PET) is arguably the most sensitive and specific molecular imaging technique. The increasing availability of molecular probes enables PET to characterize multiple physiological and pathological aspects, such as metabolism [@B21], cellular proliferation [@B22], blood flow [@B17], angiogenesis [@B23], hypoxia [@B24], and so on. Recently, we developed a NOTA (1,4,7-triazacyclononane-N,N\',N\'\'-triacetic acid)-conjugated truncated EB (NEB), which can be labeled easily with ^18^F (t~1/2~= 109.8 min) through the formation of ^18^F-aluminum fluoride complex or ^68^Ga (t~1/2~= 68.3 min) and ^64^Cu (t~1/2~= 12.6 h) through metal chelation [@B25], [@B26]. After intravenous (i.v.) injection, NEB complexes with serum albumin rapidly, and thus, most of the radioactivity is restrained to the blood circulation [@B25]. This tracer has been successfully translated into the clinic as a blood pool imaging agent [@B27] and a lymphatic mapping agent [@B28].

Since NEB shows similar *in vivo* behavior to its parental compound EB, we hypothesize here that dynamic NEB PET can be used to evaluate vascular permeability and blood volume in a non-invasive and quantitative manner. To facilitate clinical translation of this strategy, a simplified method was also established to replace dynamic acquisition and compartment modeling (Fig. [1](#F1){ref-type="fig"}). The feasibility and accuracy of this methodology was substantiated by comparison with traditional EB colorimetric assay and DCE-MRI. The changes in tumor vasculature upon treatment with bevacizumab (Avastin®), an antibody against vascular endothelial growth factor (VEGF), were successfully reflected using this technique in both drug sensitive and resistant tumor models.

Materials and Methods
=====================

Synthesis of \[^18^F\]FAl-NEB
-----------------------------

\[^18^F\]Fluoride was obtained from the National Institutes of Health (NIH) Clinical Center\'s cyclotron facility by proton irradiation of ^18^O-enriched water. The synthesis of NEB and radiolabeling procedure have been published previously [@B25]. The total synthesis and work-up time was about 20-30 min with radiochemical purity \> 95% as determined by HPLC.

Cell culture
------------

The U-87 MG human glioblastoma cells and INS-1 rat insulinoma cells were purchased from the American Type Culture Collection (ATCC, Rockville MD). UM-SCC-22B human head and neck squamous carcinoma cells were purchased from EMD Millipore (Billerica, MA). The cells were grown in Minimum Essential Medium (MEM), RPMI-1640 medium, and Dulbecco\'s modified Eagle medium (DMEM) respectively, all of which were supplemented with 10% fetal bovine serum, penicillin (100 IU/mL), and streptomycin (100 mg/mL) (Invitrogen, Carlsbad, CA) and maintained in a humidified atmosphere containing 5% CO~2~ at 37 °C. Cells were passaged three times per week.

Animal models and treatment protocol
------------------------------------

All animal studies were conducted in accordance with the principles and procedures outlined in the *Guide for the Care and Use of Laboratory Animals*[@B29] and were approved by the Institutional Animal Care and Use Committee of the Clinical Center, National Institutes of Health (NIH). Female BALB/c nude mice (age, 5-7 wk; weight, 18-20 g) were purchased from Harlan Laboratories. For tumor models, a total of 5×10^6^cells were injected subcutaneously into either right shoulder (for PET only) or right hind limb (for DCE-MRI and PET) of the nude mice. Tumor sizes were measured using a digital caliper. Tumor volume (mm^3^) was determined using the formula 0.5×length×width^2^.

When the tumors reached a volume of approximately 150 mm^3^, U-87 MG and UM-SCC-22B tumor-bearing mice were randomized into two groups to receive two doses of bevacizumab (10 mg/kg) or saline intravenously on days 0 and 3. As for doxorubicin therapy response monitoring, another group of UM-SCC-22B tumor-bearing mice were randomized to receive two doses of doxorubicin (10 mg/kg, ALZA Corporation, USA) or saline intravenously on days 0 and 3. The detailed therapy protocols are shown in Table [S1](#SM1){ref-type="supplementary-material"}.

PET and data processing
-----------------------

PET scans were obtained using an Inveon small-animal PET scanner (Siemens Medical Solutions, USA). For dynamic acquisition, 60-min dynamic PET scans were acquired in Group A (INS-1, n = 5; UM-SCC-22B, n = 5; U-87 MG, n = 6). A catheter was placed in the tail vein before each scan for tracer administration and about 5.55-7.40 MBq of \[^18^F\]FAl-NEB was injected through the catheter immediately after the scan was started. Dynamic PET data were reconstructed into 39 time frames with frame rates of 10×30s, 10×60s, 10×120s, and 9×160s. For multi-time point static PET, the tumor-bearing mice were scanned at 10, 30, and 60 min after intravenous injection of 5.55-7.40 MBq of \[^18^F\]FAl-NEB.

The images were reconstructed using 3D ordered-subsets expectation maximum followed by maximum a posteriori algorithm with a smoothing parameter of 0.1 (OSEM-3D-MAP). No correction was applied for attenuation or scatter. For each scan, regions of interest (ROIs) were drawn using vendor software (ASI Pro 5.2.4.0; Siemens Medical Solutions) on decay-corrected whole-body coronal images. The radioactivity concentrations (accumulation) within the tumor and heart were obtained from mean pixel values within the multiple ROI volumes and then converted to megabecquerel per milliliter. These values were then divided by the administered activity (assuming a tissue density of 1 g/mL) to obtain an image-ROI-derived percentage injected dose per gram (%ID/g).

To extract the tumor time-activity curves (TAC) from the dynamic PET data, the last frame of the dynamic PET image was used to define the tumor ROI and extract the TAC. Each point of the tumor TAC was given by the mean tracer tumor uptake within the defined ROI. The blood TAC was generated from the ROI over left ventricles, which was defined on the frame at the first minute. The blood TAC and the tumor TAC were then post-processed as described in the following sections to determine the tumor vascular permeability and tumor blood volume using two different approaches.

Kinetics analysis and compartment modeling
------------------------------------------

The kinetics analysis of the NEB dynamic PET was conducted to assess tumor vascular permeability. The reversible two-compartment model [@B16], [@B30] was chosen as the mathematical model for the present study. The tumor vasculature permeability could be addressed by the transport kinetics of NEB from tumor blood vasculature to tumor interstitial space, which was expressed by the diffusion equation (Eq. 1)

Where *C*~p(~t), *C*~d~(t) were the activity concentrations, as a function of time, in compartments corresponding to blood vasculature and diffusive tumor area. Since the injected dose and *in vivo* tracer concentration showed an excellent linear correlation (*R*^2^\> 0.99, Fig. [S1](#SM1){ref-type="supplementary-material"}), the %ID/g was used as the unit here instead of Bq/mL to avoid the influence of injection dose on the quantification of permeability. The *C*~p~(t) was given by the plasma input TAC generated from left ventricle ROI. *K*~PS_PET~(%ID/g/min) was the kinetic rate constant of tracer from plasma to tissue, *K*~out~ was the reflux rate (in min^-1^) from tumor back to plasma. The intensity measured in tumor ROI on PET images was a weighted sum of *C*~p~(t) and *C*~d~(t) expressed as:

Where *w*~p~ and *w*~d~ were the fractional volumes of the tumor vasculature and the diffusive compartment tumor interstitium, with *w*~d~ = (1-*w*~p~). The activity concentration in each compartment was calculated by solving the above differential equations. Given the measured TAC of tumor ROI and blood input function, the *K*~PS_PET~ and *K*~out~ were calculated by fitting the measured TAC with the analytical ROI function *C*~T~(t) (Eq. 4) using non-linear least-square regression. The goodness of fit was evaluated using residual analysis [@B31] and the error (between the data value and estimated function value) was limited to be less than 5%.

The compartmental modeling was conducted using a Matlab object-oriented toolbox. Input parameters included plasma input TAC data, tumor ROI TAC data, and initial guess of *K*~PS_PET,~ *K*~out~, and *w*~p~ values. According to literature and preliminary fitting test, the *K*~PS_PET~ and *K*~out~ were initialized to 0.01, and *w*~p~ was initialized to 0.1.

Simplified quantification of tumor vascular permeability by NEB PET
-------------------------------------------------------------------

After several minutes of tracer injection, both TACs of blood and tumor showed a linear pattern as a function of time. This phase was named as the stable state. The starting time of linearity (t = T~s~) was determined by filtering the tumor TAC data y(t) by the Eq. 1, until the *∆* inferior to a certain tolerance *ε* (e.g. 10% of ![](thnov07p2363i003.jpg)) (Fig. [S2](#SM1){ref-type="supplementary-material"}).

Where ![](thnov07p2363i005.jpg)

When the tumor and blood TAC became linear after reaching steady state at *T*~s~, the radioactivity concentrations in tumor and in blood over time, namely *C*~p~(t) and *C*~T~(t), could be expressed as a linear equation:

Where *A*~blood~ was the slope of linear blood TAC and *A*~tumor~ was the linear tumor TAC. In other words, *A*~blood~ and *A*~tumor~ were referred to as the rate of change of \[^18^F\]FAl-NEB concentration in blood and in tumor.

The \[^18^F\]FAl-NEB concentration in tumor *C*~t~(t) was contributed by two parts: the concentration in blood vasculature compartment (*C*~p~(t)) and the concentration in diffusive tumor compartment (*C*~d~(t)). The C~d~(t) started increasing from 0 as \[^18^F\]FAl-NEB permeated from vessel to tumor interstitial space. Therefore, the tumor vascular permeability could be equally represented by the change of \[^18^F\]FAl-NEB concentration in the diffusive compartment *C*~d~(t) per unit time. In the stable state, the variation of concentration changes in each compartment became constant, thus the permeability expressed by the change in *C*~d~(t) per unit time is a constant and expressed as *P*~s~ with a unit of %ID/g/min. According to Eq. 2, the change of \[^18^F\]FAl-NEB concentration in each compartment per unit time could be expressed as:

At the stable state, Eq. 5 could be integrated with the linear equation, Eq. 4, and expressed as:

Therefore, the tumor vascular permeability could be quantified by the expression (Eq.7).

The fractional volume of the tumor vasculature *w*~p~ can be calculated by Eq. 8.

,

Therefore, the tumor vascular permeability can be determined by the parameters which could all be extracted from the linear fit equation of the blood and tumor TAC as known constants (Eq. 9). Tumor blood volume (TBV) can be calculated with Eq. 10.

To evaluate the reliability of this simplified quantification method, the *P*~s~ calculated from linear equation Eq. 7 was respectively correlated with the*K*~PS-PET~ fitted from dynamic PET modeling and the *K*~PS-MRI~ derived from the modeling of DCE-MRI.

DCE MRI and data analysis
-------------------------

All the MRI scans were performed on a 9.4 T Bruker Biospec horizontal-bore MRI scanner (Bruker BioSpin, Billerica, MA) at the Mouse Imaging Facility (MIF) of the National Institutes of Health (NIH). During MRI scans, U-87 MG tumor-bearing mice (Group B, *n* = 11) were anesthetized with 1% isoflurane/air mixture and body temperature was maintained at 37°C. Dynamic contrast-enhanced MRI was performed using the *T*~1~-weighted gradient-echo sequence with the following parameters: TR/TE = 62.5/2.3 ms, flip angle = 30°, FOV = 2.56 × 1.92 cm, matrix size = 64 × 48, slice thickness = 1 mm, and averages = 1. Single or double slices across the middle of the tumor were acquired over a 15-min period, with a time resolution of 3.0 s. Following 2 min of scanning, a bolus dose of Gd-DTPA (Magnevist, Bayer Healthcare Pharmaceuticals, Whippany, NJ), with a concentration of 0.05 mM (diluted from 0.5 mM with 0.9% saline), was administered *via* tail-vein catheter in around 4 s for a volume of 100 μL. Before DCE-MRI, *T*~1~ maps were acquired on half of the animals with a saturation-recovery fast spin-echo sequence (TR = 300, 600, 1200, 1800, 3200, 8000 ms; TE = 12.75 ms) with the same geometry as DCE-MRI.

The kinetic parametric maps were determined by non-linear least-squares fitting of the time-course data in each voxel with the generalized kinetic model (Eq. 11), also called the extended Tofts-Kety model[@B32]-[@B35]:

Where *C*~t~ and *C*~p~ were the tracer concentrations in the tissue and blood plasma, respectively, *K*~PS_MRI~ was the volume transfer constant, and *v*~e~ and *v*~p~ were the extravascular extracellular volume fraction and blood plasma volume fraction in the tissue, respectively. The arterial input functions (AIF) were individually determined for each animal with an automated AIF extraction algorithm searching for the voxels containing arteries with minimal partial volume contamination in the DCE datasets [@B36]. Before the model fitting, the DCE-MRI data were visually examined and some poor-quality time points with strong subject motion were manually removed. All MRI image processing and data analyses were performed using in-house programs written in MATLAB (The Mathworks, Natick, MA, USA). On the same day, the mice from Group B also underwent dynamic \[^18^F\]FAl-NEB PET scans.

Therapy response monitoring with \[^18^F\]FAl-NEB PET
-----------------------------------------------------

For bevacizumab therapy response monitoring, U-87 MG tumor-bearing mice (Group C) in both control and treatment groups underwent \[^18^F\]FAl-NEB PET at 8 h, day 1, day 4 and day 7 post-treatment (*n*= 4-6/group), and \[^18^F\]FDG PET on day 2 post-treatment (*n*= 4/group). For therapy response monitoring in UM-SCC-22B tumors (Group D), both control and treated mice received \[^18^F\]FAl-NEB PET on days 1, 4 and 7 post-treatment (*n*= 4/group). For doxorubicin therapy response monitoring, \[^18^F\]FAl-NEB PET scans were performed in UM-SCC-22B mice (Group E) on days 1 and 4 post-treatment, and \[^18^F\]FDG PET scans were also performed on day 4 post-treatment (*n*= 4/group). The 10-min static \[^18^F\]FAl-NEB PET scans were acquired at 10, 30, and 60 min p.i., respectively, with the injection dose ranging from 5.55-7.40 MBq. The 10-min static \[^18^F\]FDG PET scans were acquired at 60 min p.i. with an injected dose of 5.55 MBq. The detailed imaging protocol is shown in Table [S1](#SM1){ref-type="supplementary-material"}.

Autoradiography
---------------

For autoradiography, at 4 h after administration of \[^18^F\]FAl-NEB, U-87 MG tumor samples were collected and frozen with dry ice after being embedded in optimum cutting temperature (O.C.T) compound (Tissue-Tek). The samples were sectioned with a cryostat (Ultrapro5000, Vibratome, St. Louis, MO). The sections were then exposed to a phosphor imaging screen in an autoradiography cassette (Fisher Biotech). 20 h later, autoradiography was performed on a Cyclone Plus Storage Phosphor System (PerkinElmer, US) and analyzed with Optiquant Acquisition and Analysis Software V5.0 (Perkin Elmer).

Evans Blue extraction and colorimetric assay
--------------------------------------------

A simplified Evans Blue extraction technique [@B7] was used to evaluate vascular permeability. At 8 h (only for the U-87 MG tumors), day 1, day 4, and day 7 post-treatment with bevacizumab, immediately after PET acquisition, Evans blue (Sigma-Aldrich) was administered intravenously at a dose of 30 mg/kg (*n*= 4/group). At 4 h after dye injection, the mice were perfused at an elevated perfusion pressure with physiological saline through the left ventricle immediately before tumor excision to remove Evans blue from blood circulation. The collected tumors were weighed and cut into pieces of approximately 50 mg/piece. Then formamide (10 μL/mg of tumor tissue) was added to extract EB from the tumor tissue for 72 h. After centrifugation, the supernatant of each tube was carefully collected, and the absorbance at 620 nm was measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc.). Note that EB extraction efficiency was measured for different tumor samples. The concentration of EB was calculated using a standard absorption curve of known concentrations of EB mixed with albumin.

CD31 staining and microvessel density
-------------------------------------

For CD31 staining, frozen slices (5 μm thick) of U-87 MG or UM-SCC-22B tumor were fixed with buffered zinc formalin fixatives (Z-fix, Anatech LTD) for 20 min and dried in the air for 30 min. The slices were rinsed with PBS for 5 min and blocked with PBS containing 1% BSA for 30 min at room temperature. The slices were then incubated with rat anti-mouse CD31 primary antibody (1:100, Abcam) for 1-h at room temperature, followed by incubation with Dylight 488-conjugated donkey anti-rat secondary antibody (1:200; Jackson Immuno-Research Laboratories, Inc.) for 40 min at room temperature. After each step, slices were washed gently with PBS containing 0.05% tween 20 (PBST) for three times, 5 min each time. All slices were mounted with mounting medium containing 4\', 6-diamidino-2-phenylindole and then observed by an epifluorescence microscope (X81; Olympus). To determine microvessel density (MVD), the areas with highest vascular density were selected, and vessels were counted in 10 random views in both the center and periphery of the tumor slices. The vessels that contained branching points were counted as a single vessel. Number of vessels counted was divided by field of view to yield MVD, as number of vessels/mm^2^.

Statistical analysis
--------------------

All data were presented as mean ± SD from at least four independent experiments. Statistical analyses were performed by SPSS software 13.0 (SPSS, Chicago, IL). An unpaired two-tailed Student\'s *t*-test was used to compare mean values including NEB tumor uptake (1 h p.i.), *K*~PS_PET,~ and Evans blue contents between treated and control groups. Slope values for tumor (*A*~tumor~) and blood (*A*~blood~) TACs were calculated from either dynamic or multi-point static PET scans using linear regression. Correlation between slope values calculated from dynamic and static scans, correlation of *P*~s~ values with EB content, *K*~PS-PET,~ or *K*~PS-MRI~ values, were all assessed using standard Pearson correlation. *P* values less than 0.05 were considered statistically significant.

Results
=======

Non-invasive evaluation of tumor blood volume and vascular permeability
-----------------------------------------------------------------------

The chemical structure of NEB was shown in Figure [1](#F1){ref-type="fig"}A. The binding of NEB with albumin is a reversible process. Due to the high concentration of albumin in the blood circulation and administration of only trace amount of NEB, the reaction is pushed to the right side to facilitate NEB-albumin complex formation and equilibrate within a few minutes postinjection (p.i.) of NEB (Fig. [1](#F1){ref-type="fig"}B). Since malignant tumors often show increased uptake and retention of high-molecular-weight nontargeted compounds, PET imaging with radiolabeled NEB provides a digital approach for noninvasive evaluation of tumor vascular permeability (Fig. [1](#F1){ref-type="fig"}C-D). Radiolabeled NEB retains the ability to bind with serum albumin as shown by the residency of radioactive signal within the blood circulation (Fig. [2](#F2){ref-type="fig"}A). Consequently, heart and major vessels showed highest signal intensity. The organs with abundant blood supply such as liver, spleen, and kidneys were also visible [@B25]. As expected, different types of tumor xenografts showed different patterns and magnitude of tracer accumulation as reflected by the tumor TACs generated from 60-min dynamic PET scans. Variance was also observed in different xenografts grown with the same cell type (Fig. [2](#F2){ref-type="fig"}B).

Conventionally, tumor uptake of a PET tracer is quantified either by percent injected dose per gram tissue (%ID/g) or standard uptake value (SUV). As shown in Fig. [2](#F2){ref-type="fig"}C, both INS-1 and UM-SCC-22B tumors showed significantly higher tracer uptake than U-87 MG tumors (7.18 ± 0.50 and 7.03 ± 0.57 *vs.* 5.14 ± 0.74 %ID/g, *P* \< 0.05) at 60 min p.i. At any given moment, the radioactivity within the tumor region would be a result of accumulation within the blood vessels and that extravasated into tumor interstitium. With a simplified linear analysis method, these two contributions can be delineated from blood and tumor TACs. INS-1 tumors showed high blood volume (18.28 ± 2.91 %), followed by UM-SCC-22B (13.98 ± 2.13 %) and U-87 MG (8.40 ± 2.26 %) (Fig. [2](#F2){ref-type="fig"}D). However, UM-SCC-22B tumor showed the highest vascular permeability *P~s~* (0.082 ± 0.008 %ID/g/min) compared with the other two tumors (INS-1, 0.062 ± 0.003 %ID/g/min; U-87 MG, 0.064 ± 0.010 %ID/g/min) (Fig. [2](#F2){ref-type="fig"}*e*). We also performed immunostaining against CD31, an endothelial cell maker, to visualize the tumor vasculature (Fig. [2](#F2){ref-type="fig"}F). However, the microvascular density (MVD) reflected by CD31 staining showed no apparent correlation with either tumor blood volume or vascular permeability.

Method simplification and substantiation
----------------------------------------

Based on the data acquired by dynamic PET, we also performed two-compartment modeling (Fig. [3](#F3){ref-type="fig"}A) and named the kinetic parameter as *K*~PS-PET~. With the same batch of mice, a significant correlation between *P~s~* and *K*~PS-PET~ was observed when *K*~PS-PET~ values were generated from the truncated TAC (10-60 min p.i.) (*R^2^*= 0.6375, *P =*0.0004, Fig. [3](#F3){ref-type="fig"}B). No correlation was found when *K*~PS-PET~ values were fit with the complete TAC (0-60 min p.i.) (*P* \> 0.05, Fig. [S2](#SM1){ref-type="supplementary-material"}).

Due to the linearity of both blood and tumor TACs once stable kinetics is attained at around 10 min p.i. (Fig. [S3](#SM1){ref-type="supplementary-material"}), we conducted static PET at 10, 30 and 60 min p.i. using 16 tumor-bearing mice in order to simplify the data acquisition and image post-processing. With the same mice, 60 min dynamic PET scan was also performed. The slopes of the linear fit on tumor and blood TACs generated from either dynamic PET (A~tumor-dyn~and A~blood-dyn~) or multiple time-point static PET (A~tumor-sta~and A~blood-sta~) were calculated. Positive and excellent linear correlations between the slopes in tumor (*R^2^*= 0.9612,*P*\< 0.0001, Fig. [3](#F3){ref-type="fig"}C) and blood (*R^2^*= 0.8778,*P*\< 0.0001, Fig. [3](#F3){ref-type="fig"}D) were observed. As a result, *P~s~*calculated from static PET correlated well with that from dynamic PET (*R*^2^= 0.7691, *P* \< 0.001, Fig. [3](#F3){ref-type="fig"}E).

We also tried to use a single time-point static scan instead of multiple time-point scans to evaluate tumor vascular permeability. The 10 min static scan at 60 min p.i. was reconstructed to 5 frames with 2 min per frame (Fig. [S4](#SM1){ref-type="supplementary-material"}). The slopes of the lines fitted from both tumor and heart TACs were calculated. For the correlation of the single-point scan (*P*~s_sin~) with multi-point scans (*P*~s_mul~), fifteen U-87 MG tumor-bearing mice were analyzed, and a moderate, but significant linear correlation was observed between *P*~s_sin~ and *P*~s_mul~. The correlation coefficients, *R^2^*, for tumor and blood between these parameters were 0.8216 and 0.5809, respectively. Based on these linear fittings, the vascular permeability calculated from the single time-point scan showed significant correlation with that from the multiple time-point scans (*R*^2^= 0.6468, *P* \< 0.001, Fig. [S4](#SM1){ref-type="supplementary-material"}D).

Comparison of PET with EB extraction and DCE-MRI
------------------------------------------------

We evaluated vascular permeability using a traditional EB extraction procedure. Xenografted mice injected with EB (30 mg/kg) were sacrificed at 4 h p.i. and perfused to remove EB containing blood. The excised tumors were extracted to measure the concentration of EB in the tumor tissue. A good correlation between measured tumor uptake of EB and the *P~s~*calculated from NEB PET was observed (n = 36, *R^2^*= 0.7404, *P*\< 0.001, Fig. [4](#F4){ref-type="fig"}A). The co-localization of NEB and EB within the tumors was also confirmed by autoradiography and bright field imaging after co-injection of ^18^F-NEB and EB (Fig. [4](#F4){ref-type="fig"}B). These data confirm that the *P*~s~ value from NEB PET could be used to evaluate the level of vascular permeability accurately.

DCE-MRI is a widely used method to evaluate vascular permeability. Thus, we further compared *P~s~* calculated from NEB PET and *K*~PS-MRI~generated from DCE-MRI using Gd-DPTA as a contrast agent in U-87 MG tumor mice. NEB PET was performed within 24 h after DCE-MRI on the same U-87 MG mice. A moderate, but significant positive correlation was found between *P*~s~ and the MRI-derived parameter*K*~PS-MRI~(*R^2^*= 0.533, *P \< 0.05*, Fig. [4](#F4){ref-type="fig"}C). The *T*~1~-weighted MRI and *K*~PS-MRI~ parametric map are presented in Fig. [S5](#SM1){ref-type="supplementary-material"} and Fig. [4](#F4){ref-type="fig"}D.

NEB PET of vascular permeability change after treatment
-------------------------------------------------------

Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A), was the first clinically available angiogenesis inhibitor in the United States [@B37]. After treatment with 2 doses of bevacizumab, the U-87 MG tumors showed a partial response, reflected by significant growth inhibition at day 4 after the treatment started (*P*\< 0.05; Fig. [5](#F5){ref-type="fig"}A). Tumor accumulation of NEB at 60 min p.i. decreased significantly in the treatment group compared to the control group on days 1, 4 and 7 after treatment (2.88 ± 0.24 *vs.* 5.92 ± 0.62 %ID/g, *P* \< 0.01; 2.10 ± 0.32 *vs.* 5.62 ± 0.42 %ID/g, *P* \< 0.01; and 2.32 ± 0.15 *vs.* 6.03 ± 0.53 %ID/g, *P* \< 0.01; respectively). However, at 8 h after treatment, no significant difference of tumor uptake was observed (4.20 ± 1.08 *vs.* 4.89 ± 0.81 %ID/g, *P* = 0.23) (Fig. [5](#F5){ref-type="fig"}B and [5](#F5){ref-type="fig"}C).

Based on the 10, 30, and 60 min NEB PET, the tumor blood volume and the vascular permeability parameter *P*~s~ values were calculated. As shown in Fig. [5](#F5){ref-type="fig"}D and [5](#F5){ref-type="fig"}E decreased tumor blood volume and tumor vascular permeability was observed on days 1, 4, and 7 after bevacizumab treatment. At early stage of the treatment (8 h) no apparent difference in tumor blood volume was observed, while *P~s~* in the treatment group was significantly lower than that in the control group (0.046 ± 0.011 *vs.* 0.063 ± 0.0149 %ID/g/min, *P* = 0.04). The change of tumor vascular permeability induced by bevacizumab treatment was confirmed by EB extraction and colorimetric assay (Fig. [5](#F5){ref-type="fig"}F). Decreased CD31 staining and MVD was also observed in treated tumors (Fig. [5](#F5){ref-type="fig"}G and [5](#F5){ref-type="fig"}H). Interestingly, compared with the control group, no significant difference in \[^18^F\]FDG uptake, a measure of tumor glucose metabolism, was observed in bevacizumab treated tumors (5.97 ± 0.92 *vs.* 6.47 ± 1.12 %ID/g, *P* = 0.454) at 2 days after the first therapeutic dose (Fig. [S6](#SM1){ref-type="supplementary-material"}).

Different from U-87 MG, UM-SCC-22B tumors are not sensitive to bevacizumab treatment (Fig. [S7](#SM1){ref-type="supplementary-material"}A). Consequently, no apparent difference with respect to tumor uptake of \[^18^F\]FAl-NEB in the treatment *vs.* control group was observed. Both tumor blood volume and *P*~s~ were very similar between control and bevacizumab-treated groups (*P*\> 0.05) at all time-points. The results from EB colorimetric assay and CD31 staining were also consistent with the results from NEB PET (Fig. [S7](#SM1){ref-type="supplementary-material"}F and Fig. [S8](#SM1){ref-type="supplementary-material"}).

We also applied NEB PET to assess the response of UM-SCC-22B tumors to an effective chemotherapeutic drug, doxorubicin (Fig. [6](#F6){ref-type="fig"}). Regarding PET-derived parameters, the differences between treated and control tumors were not found to be statistically significant: on day 1 (NEB uptake, 5.29 ± 0.29 *vs.* 5.85 ± 0.29 %ID/g; tumor blood volume, 11.78 ± 1.36 *vs.* 11.17 ± 1.10 %; *P*~s~, 0.064 ± 0.009 *vs.* 0.074 ± 0.008 %ID/g/min), but on day 4 post-treatment (NEB uptake, 3.50 ± 0.42 *vs.* 5.64 ± 0.16 %ID/g, *P* \< 0.05; tumor blood volume, 8.69 ± 0.67 *vs.* 12.16 ± 0.42, *P* \< 0.05: *P*~s~, 0.0328 ± 0.0027 %ID/g/min *vs.* 0.0605 ± 0.0058 %ID/g/min;*P*\< 0.05). These results implied that NEB PET can identify the change in tumor vasculature after treatment by chemotherapeutics.

Discussion
==========

Malignant tumors often show increased uptake and retention of high-molecular weight molecules or nanoparticles, which is known as the enhanced permeability and retention (EPR) effect. Furthermore, angiogenesis and vasculature vary in different types of tumors. Therefore, the ability to evaluate tumor vasculature and permeability would be helpful for patient preselection and response assessment. The azo-dye EB has been intensively and increasingly applied for several biological and physiological assays including blood permeability, blood-brain barrier (BBB) disruption, and epithelial disruption [@B38]-[@B41]. However, this method is limited to preclinical studies due to its invasiveness. In this study, by applying the same principle, we developed a new method to evaluate vascular permeability non-invasively by using NEB PET. For colorimetric assay using EB dyes, a thorough perfusion is needed to remove the EB dye in the blood circulation in order to quantify the amount of extravasated EB-albumin complex. With NEB PET, the signal from NEB-albumin complex within the tumor blood pool can be subtracted by kinetic modeling or simplified linear slope differentiation of TACs from blood and tumor. The positive and significant linear correlation between *P*~s~ calculated from NEB PET and tumor EB amount substantiated that *P*~s~ would be an effective parameter to noninvasively evaluate the level of tumor vascular permeability.

It is well known that the exact physiological meaning of parameters derived from kinetic modelling is complex and not related to a single process such as blood flow or blood volume only [@B32]. In most cases, the parameters frequently indicate a combination of flow and vascular permeability. In the cases of high blood perfusion, such as INS-1 tumor, the flux of contrast agent into the interstitial space is blood flow limited and *K*~PS~ extracted from DCE-MRI kinetic modeling will approximate tissue perfusion. On the other hand, when blood perfusion is low and vascular permeability is high, such as in U-87 MG tumor, *K*~PS~ is weighted more for vascular permeability. This may partially explain the fact that only a moderate correlation (*R*^2^= 0.5331) was established between *P*~s~ values from NEB PET and *K*~PS_MRI~ from DCE-MRI.

Although several parameters can be calculated after dynamic acquisition and compartment modeling, the highly demanding technique is a hurdle for both preclinical and clinical applications. The data analysis of NEB PET can be simplified due to the almost perfect linearity of both blood and tumor TACs once a steady state of NEB in blood is reached. Both the tumor blood volume fraction and vascular permeability can be quantified using the data from 10 to 60 min. This procedure would be appropriate for most clinical applications, but for some preclinical investigations where large number of animals need to be scanned, this acquisition procedure is relatively inefficient. Therefore, we adopted multiple time-point static scans instead of a single long dynamic scan. As expected, a decent correlation was identified between *P~s~,* resulting from these different acquisition procedures.

Since anti-angiogenesis therapies rarely lead to regression of established tumors [@B42], [@B43], measurement of vascular permeability could provide alternative end-points to assess tumor vascular effects of antiangiogenic agents [@B44]. With NEB PET, we evaluated the change of vascular permeability and blood volume in tumor models after being treated with bevacizumab, or doxorubicin. It has been reported that anti-VEGF treatment could result in a decrease in microvascular density, vascular permeability, and interstitial fluid pressure [@B45], [@B46]. Consistently, both tumor blood volume and vascular permeability reflected by NEB PET decreased significantly upon bevacizumab treatment in U-87 MG tumors. Specifically, the decreases of *P*~s~ values in treated mice could be observed as early as 8 h after treatment, which is 3 days before the alteration in tumor volume becomes obvious. Our data also supported the notion that the alteration in tumor vascular permeability precedes the changes in tumor blood flow (perfusion) and glucose metabolism [@B45]-[@B46]. However, in bevacizumab-resistant UM-SCC-22B tumors, NEB uptake showed little change between control and treated groups, even following two doses of bevacizumab, neither did the *P*~s~ values or tumor blood volume change significantly. The PET results from this resistant tumor type were also consistent with the histological results and EB extraction data. These results demonstrated that monitoring tumor vascular permeability using NEB PET can be applied to early assessment of tumor responsiveness to antiangiogenic therapy. Besides anti-angiogenesis drugs, some chemotherapeutics may also induce changes in tumor vasculature, either directly or indirectly [@B47], [@B48]. Our results demonstrated that the vasculature changes induced by doxorubicin in UM-SCC-22B tumor could be identified by NEB PET.

Compared with other methods, NEB PET has several advantages to evaluate vascular permeability. Firstly, due to the high sensitivity of PET, only trace amount of radiolabeled NEB is needed, which avoids the potential toxicity of EB [@B49] and facilitates effective complexation of NEB to serum albumin. Secondly, the quantitative nature of PET guarantees the accuracy of evaluation. The PET signal was directly associated with serum albumin concentration. The unit of *P~s~* is %ID/g/min and a typical tumor will give a value of 0.05 %ID/g/min. If we assume the initial blood distribution of NEB in blood is 30 %ID/g and serum albumin concentration is 30 mg/mL [@B50], the *P~s~* would be 0.05 mg/g/min, which means that in one minute, 0.05 mg serum albumin will extravasate to interstitial space per gram tumor tissue. Thirdly, NEB can be easily labeled with various radioisotopes with a total synthesis time of less than 30 min, including purification and sterile reconstitution as an injectable. This would lower the barrier for both preclinical studies and clinical applications. Besides tumor vascular permeability we have investigated in this study, NEB PET has the potential to be applied to many cases in which Evans Blue has been used to evaluate vascular permeability, protein transfer across the endothelial barrier, and loss of integrity of the BBB [@B51]. If the targets of interest have low blood supply, the outlining of ROI may be challenging due to the non-ideal spatial resolution of PET. This problem can be solved by multiple-modality imaging such as PET/CT or PET/MRI, in which CT or MRI can provide excellent morphological resolution to define the lesion borders [@B52].

In summary, we have established an innovative strategy based on NEB PET to noninvasively evaluate vascular permeability. Tumor vascular permeability and blood volume fraction can be noninvasively quantified, which could provide functional vascular parameters for patient pre-selection, response monitoring following antiangiogenic therapy, and guiding drug delivery.
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![(A) Chemical structure of NOTA conjugated truncated Evan\'s Blue (NEB) and radiolabeling of NEB with ^18^F-aluminum (\[^18^F\]FAl). (B) The reversible complexation of \[^18^F\]FAl-NEB with serum albumin (Alb), forming the macromolecule NEB-Alb. (C) Schematic of enhanced permeability and retention (EPR) effect within the solid tumor as a result of fenestrated endothelial junctions allowing extravasation of NEB-Alb from plasma to interstitial fluid. (D) Representative time-activity curves (TACs) of tumor and blood derived from 60-min dynamic PET scans after administration of \[^18^F\]FAl-NEB. The radioactivity within the tumor region results from two components: the tracer within the blood vessels and that extravasated into tumor interstitium. With a simplified linear analysis method, the two components can be delineated based on the TACs of blood and tumor.](thnov07p2363g001){#F1}

![(A) Series of maximum-intensity-projection (MIP) PET images of INS-1, UM-SCC-22B, and U-87 MG tumor-bearing mice after intravenous injection of \[^18^F\]FAl-NEB. Each mouse received around 5.55 MBq of radioactivity. Images were reconstructed from a 60-min dynamic scan. Tumors are indicated by the white arrows. (B) Tumor TACs derived from 60-min dynamic PET scans after administration of \[^18^F\]FAl-NEB. (C-E) PET quantification of tumor \[^18^F\]FAl-NEB uptake (%ID/g), tumor blood volume (%), and vascular permeability (*P*~s~in %ID/g/min). Unpaired *t* test was used to evaluate differences. (F) CD31 staining of tumor sections. The tumor slices were incubated with rat anti-mouse CD31 primary antibody followed by incubation with Dylight 488-conjugated donkey anti-rat secondary antibody. All slices were mounted with mounting medium containing 4\', 6-diamidino-2-phenylindole (DAPI).](thnov07p2363g002){#F2}

![(A) Two-compartment kinetic model describing the kinetics of \[^18^F\]FAl-NEB from plasma to interstitial fluid. (B) Correlation of *P*~s~ with PET-derived kinetic parameter *K*~PS-PET~. *K*~PS-PET~ was calculated by the dynamic frames from 10 to 60 min. (C-D) Correlation between slope values from tumor (C) or blood (D) TAC measured by dynamic NEB PET (*P*~s_dyn~) and those measured by multi-point static PET (*P*~s_mul~). (E) Correlation of *P*~s~ values measured by dynamic NEB PET (*P*~s_dyn~) with *P*~s~ measured by multi-point static PET (*P*~s_mul~). Solid line denotes the best fit linear correlation line. Pearson correlation coefficient *R*^2^, and *P* value of linear regression are shown.](thnov07p2363g003){#F3}

![(A) Correlation of *P*~s~ measured by NEB PET with EB amount measured by EB extraction method. (B) EB extravasation shows the distribution pattern of blue coloration in U-87 MG tumor tissues (left), and autoradiography shows the distribution pattern of \[^18^F\]FAl-NEB radioactivity in corresponding tumor area (right). (C) Correlation of *P*~s~ with MRI-derived parameter *K*~PS-MRI~. (D) Small animal MRI and *K*~PS-MRI~ parametric maps. Left image shows contrast-enhanced MRI in the U-87MG tumor region (10 min p.i.), and the right image shows the corresponding parametric maps of *K*~PS-MRI~ in the tumor region.](thnov07p2363g004){#F4}

![(A) U-87 MG tumor growths with and without bevacizumab treatment. (B) Representative maximum-intensity-projection (MIP) NEB PET images (1 h p.i.) acquired from control and bevacizumab-treated U-87 MG tumor xenografts at 8 h, day 1, day 4 and day 7 post-treatment. (C-F) PET Quantification of tumor \[^18^F\]FAl-NEB uptake (C), blood volume (D), *P*~s~ values (E), and Evans blue amount (F) in bevacizumab-treated and control U-87 MG tumors. Unpaired *t* test was used to evaluate differences. \**P* ≤ 0.05, \*\**P* ≤ 0.01. White column represents control group and black column represents bevacizumab-treated group. (G) Immunofluorescence staining of CD31 in ex vivo tumor tissue from bevacizumab-treated and control U-87 MG tumor bearing mice at 8 h, day 1, day 4 and day 7 post-treatment (magnification×100). (H) MVD measurement of control and bevacizumab-treated U-87 MG tumors. Number of vessels counted was divided by field of view to yield MVD, as number of vessels/mm^2^. Unpaired *t* test was used to evaluate differences. \**P* ≤ 0.05, \*\**P* ≤ 0.01. White column represents control group and black column represents bevacizumab-treated group.](thnov07p2363g005){#F5}

![Evaluation of tumor response to doxorubicin therapy. (A) Tumor growth study of mice with UM-SCC-22B xenografts treated with doxorubicin. (B) Representative coronal NEB PET images acquired from control and doxorubicin-treated UM-SCC-22B tumor xenografts on days 1 and 4 post-treatment. Images shown here were acquired at 60 min p.i., Tumors are indicated by the white arrow. (C-D) PET quantification of tumor blood volume (C), \[^18^F\]FAl-NEB uptake (D), and *P~s~* values (E) in doxorubicin-treated and control UM-SCC-22B tumors. Unpaired *t* test was used to evaluate differences. \**P* ≤ 0.05, \*\**P* ≤ 0.01. Black column = doxorubicin-treated, white column = control.](thnov07p2363g006){#F6}
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